X-linked hypophosphataemia

The PBS subsidises burosumab for patients with X-linked hypophosphataemia (XLH).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with burosumab under the National Health Act 1953, section 100 for adult patients with X-lined hypophosphataemia (XLH).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing burosumab.

Section 100 arrangements

Burosumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital provider number for the authority application.

Treatment specifics

To be eligible for PBS-subsidised treatment with burosumab, patients must be treated by a medical practitioner identifying as at least one of the following specialists:

  • paediatric endocrinologist
  • paediatric nephrologist
  • endocrinologist
  • nephrologist.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised burosumab to treat X-linked hypophosphataemia can be made either:

Applying for initial grandfather treatment

For patients who received non-PBS-subsidised burosumab treatment before 1 November 2022 for X-linked hypophosphataemia, apply for initial grandfather authority approval either:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised burosumab to treat X-linked hypophosphataemia can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 November 2022.